ScholarIQanswers from OpenAlex
Jnana Therapeutics (United States)
InstitutionResearch output, impact & collaborations
Jnana Therapeutics (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Jnana Therapeutics (United States)?
ScholarIQrecord summary
Jnana Therapeutics (United States) is a research organisation in Boston, United States. OpenAlex records 63 works and 7,762 citations for it. 3 researchers list it as their most recent affiliation.
How many works does Jnana Therapeutics (United States) have?
ScholarIQindexed works
Jnana Therapeutics (United States) has 63 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jnana Therapeutics (United States) have?
ScholarIQcitation count
Jnana Therapeutics (United States) has 7,762 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Jnana Therapeutics (United States)?
ScholarIQresearcher count
Jnana Therapeutics (United States) has 3 researchers in the ScholarIQ index.
What is the average h-index at Jnana Therapeutics (United States)?
ScholarIQavg h-index
Jnana Therapeutics (United States) has an average h-index of 51.7 in OpenAlex.
What is the ROR of Jnana Therapeutics (United States)?
ScholarIQror
The ROR for Jnana Therapeutics (United States) is on the source record.
What is the OpenAlex record for Jnana Therapeutics (United States)?
ScholarIQopenalex
The OpenAlex for Jnana Therapeutics (United States) is on the source record.
Who are the most-cited researchers behind Jnana Therapeutics (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Jnana Therapeutics (United States)?
ScholarIQmost cited works
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina, Giordano Caponigro, Nicolas Stransky, K. Venkatesan, Adam A. Margolin, Sung Joon Kim, Christopher J. Wilson, Joseph Lehár, Gregory V. Kryukov, Dmitriy Sonkin, Anupama Reddy, Manway Liu, Lauren Murray, Michael F. Berger, John E. Monahan, Paula Morais, Jodi Meltzer, Adam Korejwa, Judit Jané‐Valbuena, Felipa Mapa, Joseph Thibault, Eva Bric-Furlong, Pichai Raman, Aaron Shipway, Ingo H. Engels, Jill Cheng, Guoying Karen Yu, Jianjun Yu, Peter Aspesi, Melanie de Silva, Kalpana Jagtap, Michael D. Jones, Li Wang, Charlie Hatton, Emanuele Palescandolo, Supriya Gupta, Scott Mahan, Carrie Sougnez, Robert C. Onofrio, Ted Liefeld, Laura E. MacConaill, Wendy Winckler, Michael Reich, Nanxin Li, Jill P. Mesirov, Stacey Gabriel, Gad Getz, Kristin Ardlie, Vivien W. Chan, Vic E. Myer, Barbara L. Weber, Jeff Porter, Markus Warmuth, Peter M. Finan, Jennifer L. Harris, Matthew Meyerson, Todd R. Golub, Michael Morrissey, William R. Sellers, Robert Schlegel, Levi A. Garraway
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
Jean‐François Emile, Oussama Abla, Sylvie Fraitag, AnnaCarin Horne, Julien Haroche, Jean Donadieu, Luis Requena‐Caballero, Michael B. Jordan, Omar Abdel‐Wahab, Carl E. Allen, Frédéric Charlotte, Eli L. Diamond, R. Maarten Egeler, Alain Fischer, Juana Gil Herrera, Jan‐Inge Henter, Filip Jankú, Miriam Mérad, Jennifer Picarsic, Carlos Rodríguez‐Galindo, Barret J. Rollins, Abdellatif Tazi, Robert Vassallo, Lawrence M. Weiss
Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer
Scott Kopetz, Jayesh Desai, Emily Chan, J. Randolph Hecht, Peter J. O’Dwyer, Dipen M. Maru, Van K. Morris, Filip Jankú, Arvind Dasari, Woonbok Chung, Jean‐Pierre J. Issa, Peter Gibbs, Brian P. James, Garth Powis, K. B. Nolop, Suman Bhattacharya, Leonard B. Saltz
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Apostolia M. Tsimberidou, Nancy G. Iskander, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Siqing Fu, Sarina A. Piha‐Paul, Aung Naing, Filip Jankú, Rajyalakshmi Luthra, Ye Yang, Sijin Wen, Donald A. Berry, Razelle Kurzrock
Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
Thomas H. Marsilje, Wei Pei, Bei Chen, Wenshuo Lu, Tetsuo Uno, Yunho Jin, Tao Jiang, Sung Joon Kim, Nanxin Li, Markus Warmuth, Yelena Sarkisova, Frank F. Sun, Auzon Steffy, AnneMarie Culazzo Pferdekamper, Allen G. Li, Sean B. Joseph, Young Ho Kim, Bo Liu, Tove Tuntland, Xiaoming Cui, Nathanael S. Gray, Ruo W. Steensma, Yongqin Wan, Jiqing Jiang, Greg Chopiuk, Jie Li, W. Perry Gordon, Wendy Richmond, Kevin C. Johnson, Jonathan Chang, Todd Groessl, You-Qun He, Andrew Phimister, J. Alex Aycinena, Christian C. Lee, Badry Bursulaya, Donald S. Karanewsky, H. Martin Seidel, Jennifer L. Harris, Pierre‐Yves Michellys
How much of the research on Jnana Therapeutics (United States) is open access?
ScholarIQopen access share
88%OPEN ACCESS